Choreo LLC’s Novo Nordisk NVO Stock Holding History

Choreo LLC’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.05M	Sell	106,820 -10,208	-9%	-$484K	0.05%	250
2025 Q4	$5.99M	Sell	117,028 -3,208	-3%	-$164K	0.08%	178
2025 Q3	$6.67M	Buy	120,236 +1,635	+1%	+$95.7K	0.09%	160
2025 Q2	$8.19M	Sell	118,601 -4,427	-4%	-$301K	0.11%	126
2025 Q1	$8.68M	Sell	123,028 -4,936	-4%	-$408K	0.13%	115
2024 Q4	$11M	Buy	127,964 +79,098	+162%	+$8.55M	0.16%	106
2024 Q3	$5.77M	Buy	48,866 +4,128	+9%	+$551K	0.08%	168
2024 Q2	$6.49M	Buy	44,738 +41,111	+1,133%	+$5.45M	0.11%	126
2024 Q1	$466K	Buy	3,627 +519	+17%	+$61.8K	0.01%	441
2023 Q4	$322K	Buy	3,108 +194	+7%	+$19.2K	0.01%	478
2023 Q3	$265K	Sell	2,914 -58	-2%	-$5.11K	0.01%	388
2023 Q2	$240K	Sell	2,972 -30	-1%	-$2.45K	0.01%	414
2023 Q1	$241K	Buy	+3,002	New	+$213K	0.01%	426

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Choreo LLC's NVO Position: Q1 2026 in Review

Choreo LLC reduced its Novo Nordisk (NVO) stake by 8.7% in Q1 2026, selling an estimated $484K and leaving 106,820 shares worth $4.05M. The position accounts for 0.05% of the portfolio, ranked #250.

Choreo LLC first reported a position in NVO in Q1 2023 and has held it in 13 quarters since. The position peaked at $11M in Q4 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Choreo LLC held 106,820 shares of Novo Nordisk worth $4.05M as of Q1 2026.
Choreo LLC sold 10,208 Novo Nordisk shares in Q1 2026, an estimated $484K.
Novo Nordisk made up 0.05% of Choreo LLC's portfolio in Q1 2026, its #250 holding.
Choreo LLC first reported a position in Novo Nordisk in Q1 2023 and has held it in 13 quarters since.
Choreo LLC's Novo Nordisk position peaked at $11M in Q4 2024.
1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Choreo LLC's 13F filing for Q1 2026, filed 13 May 2026.